



ATORVASTATIN + TELMISARTAN Tablets

Innovative Fixed
dose combination
(FDC) supported
by guidelines*

- **Indicated for** the treatment of essential hypertension and/or stable ischemic heart disease in connection with primary hypercholesterolemia or mixed (combined) hyperlipidemia, as a substitute therapy in adult patients adequately controlled with Atorvastatin and Telmisartan administered simultaneously in the same dose as contained in this combination, but as separate preparations

Targeted for
substitution therapy

Available strengths: 10+40mg, 20+40mg, 40+40mg,
80+40mg, 10+80mg, 20+80mg, 40+80mg, 80+80mg

Higher patient
compliance

Both substances already used in standard therapy of hypertension and/or hyperlipidemia

- This inter class combination treatment has been recommended by the Chairman of the Czech Internal Medicine Society
- The rationale is to increase the adherence to Atorvastatin treatment
- Telmisartan adherence is better as patients notice non-compliance, by combining with Atorvastatin, Atorvastatin adherence will be increased

Reference markets

- Atorvastatin remains the largest statin sold 9.5b Tab sold (MAT Q2 2022) as per IQVIA in EU27+UK
- Amlodipine + Perindopril + Atorvastatin received 53m Tablets sold vs Amlodipine + Perindopril reference market of 921m, showing greater than 5% conversion (MAT Q2 2022)

*Ref - <https://academic.oup.com/eurheartj/article/39/33/3021/5079119?login=false>

Regulatory pathway

- Legal basis: Article 10b fixed dose combination

Development status

- Prototype development
- Clinical Strategy: PK studies +co-prescription data / literature information EU dossier expected to be completed by Q4/2024

Partnership options

- Product is available for out-licensing in selected markets in Europe on exclusive or semi-exclusive base
- Dossier can be adjusted to markets outside Europe based on request

DISCLAIMER: Any disposal with the product, including but not limited to the development, sale and offer for sale of products and related processes identified within this catalogue is performed by Zentiva only in those territories where it is permissible by applicable patent law; in particular, but not limited to Art. 10 EC Directive 2001/83. This catalogue shall not constitute an offer for sale of products and processes for the territories where an offer for sale or sale is not permissible by law. Zentiva expressly disclaims any liability for damages resulting from or arising out of the unauthorised use of such products and related processes.